Natalie S. Chen

Natalie S. Chen

Auto-generated profile, based on publicly available information

Natalie S. Chen

Department of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
KYKevin Yen
Kevin Yen
SBSonali Belapurkar
Sonali Belapurkar
CPCassidy Puckett
Cassidy Puckett
NCNatalie S. Chen
Natalie S. Chen
LYLoren Yglecias
Loren Yglecias
JWJenise C. Wong
Jenise C. Wong
Background: Disparities in outcomes and technology use in children with Type 1 diabetes (T1D) from underresourced backgrounds are well documented. The feasibility of initiating automated insulin delivery (AID) soon after diagnosis of T1D is less certain in this population. This pilot study assessed the feasibility and acceptability of providing access to the Tandem Control‐IQ AID system to children with public insurance soon after T1D diagnosis. Methods: Publicly insured children aged 6–21 years of age within 3 months of T1D diagnosis were eligible for the study. Participants were randomized 2:1 to AID or usual care for 6 months. Continuous glucose monitoring data were collected at baseline, 3 months, and 6 months. Caregivers and youth completed closing surveys and participated in focus group interviews to assess safety and user experience. Results: Nineteen youth were enrolled, with thirteen in the intervention and six in the control group. The mean age was 11.5 ± 2.3 years, 47% were female, and 89% were from underrepresented racial or ethnic groups. A larger proportion of the AID group compared to the control group achieved the American Diabetes Association benchmark of > 70% time in range (50% vs. 0% of participants at 3 months; 37% vs. 0% of participants at 6 months; not statistically significant). All caregivers and 69% of youth in the AID group reported satisfaction, and 85% of youth continued using AID 6 months after the completion of the study. Focus groups showed favorable experiences with AID use. Conclusion: Early initiation of AID is feasible and acceptable in youth with recently diagnosed T1D from underresourced populations who historically experience lower technology adoption and less optimal glycemic outcomes. Diabetes clinicians should consider providing tailored support and dedicated resources to families early in diagnosis with T1D to promote AID initiation and continued use.

21 October 2025 in bioRxiv
Verified
Preprint
Open access
KNKaori Noridomi
Kaori Noridomi
JIJ. Mario Isas
J. Mario Isas
AAAnakha Ajayan
Anakha Ajayan
TMTristan McPhail
Tristan McPhail
HXHui Xu
Hui Xu
RRRichard W. Roberts
Richard W. Roberts
In Huntingtons disease, polyglutamine expansion in huntingtin exon 1 (Httex1) results in stepwise misfolding, amyloid formation, and neuronal death. Here we used mRNA display directed evolution to generate peptide ligands targeting Httex1 protofibrils, an early, toxic misfolding intermediate. Two distinct peptide families bind protofibrils, one tryptophan rich and the other glutamine rich, resulting in two predominant peptides HD1 (W-rich) and HD8 (Q-rich). Both peptides bind with high affinity and specificity to the misfolded polyQ structure present in protofibrils, a toxic component that is not recognized by existing huntingtin-directed antibodies. Homo- and heterodimers of HD1 and HD8 bind protofibrils with antibody-like affinity, and potently inhibit aggregation of recombinant and cellular Httex1. The HD8-1 heterodimer can be used like an antibody for immunocytochemistry to identify Httex1 aggregates in transfected cells and in the retina of a Huntingtons disease mouse model system (R6/1). Peptide binding to both in vitro and in vivo Httex1 validates in vitro generated Httex1 protofibrils share the same structural features as Httex1 amyloid from cellular and mammalian disease model systems. Further, HD8-1 protofibril recognition enables direct detection of a pathogenic form of Httex1 (misfolded polyQ) as a disease biomarker. Finally, HD1, HD8, and HD8-1 binding and aggregation inhibition defines the protofibril sites that mediate fibril growth. Overall, our observations support developing protofibril-directed ligands as novel, selective, diagnostics and therapeutics for Huntingtons disease. Significance Statement: Huntingtin protein polyQ misfolding plays a central role in Huntington’s disease pathogenesis. We used mRNA display to discover a new class of huntingtin-directed ligands protofibril-binding peptides. Unlike presently available antibodies, these peptides selectively recognize misfolded polyQ region, enable using toxic huntingtin aggregates as disease biomarkers, and block huntingtin aggregation in vitro and in vivo . Protofibril binding peptides may thus assist analysis of huntingtin pathology and provide a starting point for designing protein misfolding inhibitors as Huntington’s disease therapeutics.